iSign Solutions (ISGN) 10-Q 14 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 14, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	iSign Solutions Inc.
Entity Central Index Key	0000727634
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Ex Transition Period	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,761,980
Entity File Number	000-19301
Entity Interactive Data Current	Yes
Entity Incorporation state Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 37	$ 335
Accounts receivable, net of allowance of $0 at September 30, 2019 and $1 at December 31, 2018, respectively	61	84
Prepaid expenses and other current assets	36	46
Total current assets	134	465
Property and equipment, net	9	2
Other assets	5	5
Total assets	148	472
Current liabilities:
Accounts payable	1,249	1,280
Short-term debt	2,239	2,210
Accrued compensation	72	81
Other accrued liabilities	744	524
Deferred revenue	293	281
Total current liabilities	4,597	4,376
Deferred revenue long-term		36
Other long-term liabilities	613	665
Total liabilities	5,210	5,077
Commitments and contingencies
Stockholders’ equity (deficit):
Common stock, $0.01 par value; 2,000,000 shares authorized; 5,760 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	58	58
Treasury shares, 5 at September 30, 2019 and December 31, 2018, respectively	(325)	(325)
Additional paid-in capital	129,607	129,251
Accumulated deficit	(13,440)	(133,589)
Total stockholders’ deficit	(5,062)	(4,605)
Total liabilities and stockholders’ deficit	$ 148	$ 472

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance	$ 0	$ 1
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	2,000,000	2,000,000
Common stock, shares issued	5,760	5,760
Common stock, shares outstanding	5,760	5,760
Treasury shares	5	5

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue:
Product	$ 45	$ 24	$ 126	$ 97
Maintenance	168	173	512	539
Total revenue	213	197	638	636
Cost of sales:
Product	5	2	8	7
Maintenance	23	28	56	46
Research and development	179	166	531	632
Sales and marketing	10	14	63	75
General and administrative	147	179	541	507
Total operating costs and expenses	364	389	1,199	1,267
Loss from operations	(151)	(192)	(561)	(631)
Warrant expenses on long−term liabilities	(47)		(47)
Other income (expense), net		90	14	46
Interest expense:
Related party	(19)	(9)	(46)	(25)
Other	(46)	(36)	(142)	(100)
Amortization of debt discount:
Related party	(3)	(14)	(8)	(28)
Other	(7)	(34)	(22)	(72)
Loss before income tax expense	(273)	(195)	(812)	(810)
Income tax expense			(1)	(2)
Net loss	$ (273)	$ (195)	$ (813)	$ (812)
Basic and diluted net loss per common share	$ (0.05)	$ (0.03)	$ (0.14)	$ (0.14)
Weighted average common shares outstanding, basic and diluted	5,760	5,760	5,760	5,760

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 58	$ (325)	$ 129,027	$ (132,562)	$ (3,802)
Balance, shares at Dec. 31, 2017	5,760	5
Stock-based compensation			48		48
Net loss				(284)	(284)
Balance at Mar. 31, 2018	$ 58	$ (325)	129,075	(132,846)	(4,038)
Balance, shares at Mar. 31, 2018	5,760	5
Balance at Dec. 31, 2017	$ 58	$ (325)	129,027	(132,562)	(3,802)
Balance, shares at Dec. 31, 2017	5,760	5
Net loss					(812)
Balance at Sep. 30, 2018	$ 58	$ (325)	129,170	(133,374)	(4,471)
Balance, shares at Sep. 30, 2018	5,760	5
Balance at Mar. 31, 2018	$ 58	$ (325)	129,075	(132,846)	(4,038)
Balance, shares at Mar. 31, 2018	5,760	5
Stock-based compensation			27		27
Net loss				(333)	(333)
Balance at Jun. 30, 2018	$ 58	$ (325)	129,102	(133,179)	(4,344)
Balance, shares at Jun. 30, 2018	5,760	5
Stock-based compensation			68		68
Net loss				(195)	(195)
Balance at Sep. 30, 2018	$ 58	$ (325)	129,170	(133,374)	(4,471)
Balance, shares at Sep. 30, 2018	5,760	5
Balance at Dec. 31, 2018	$ 58	$ (325)	129,251	(133,589)	(4,605)
Balance, shares at Dec. 31, 2018	5,760	5
Stock-based compensation			59		59
Net loss				(291)	(291)
Balance at Mar. 31, 2019	$ 58	$ (325)	129,310	(133,880)	(4,837)
Balance, shares at Mar. 31, 2019	5,760	5
Balance at Dec. 31, 2018	$ 58	$ (325)	129,251	(133,589)	(4,605)
Balance, shares at Dec. 31, 2018	5,760	5
Net loss					(813)
Balance at Sep. 30, 2019	$ 58	$ (325)	129,607	(134,402)	(5,062)
Balance, shares at Sep. 30, 2019	5,760	5
Balance at Mar. 31, 2019	$ 58	$ (325)	129,310	(133,880)	(4,837)
Balance, shares at Mar. 31, 2019	5,760	5
Stock-based compensation			48		48
Net loss				(249)	(249)
Balance at Jun. 30, 2019	$ 58	$ (325)	129,358	(134,129)	(5,038)
Balance, shares at Jun. 30, 2019	5,760	5
Stock-based compensation			37		37
Warrants issued associated with other long-term labilities			212		212
Net loss				(273)	(273)
Balance at Sep. 30, 2019	$ 58	$ (325)	$ 129,607	$ (134,402)	$ (5,062)
Balance, shares at Sep. 30, 2019	5,760	5

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (813)	$ (812)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	49	3
Debt discount amortization	30	100
Loss on disposal of fixed assets		8
Stock-based compensation	144	143
Changes in operating assets and liabilities:
Accounts receivable, net	23	(27)
Prepaid expenses and other current assets	10	(27)
Accounts payable	(31)	11
Accrued compensation	(9)	(61)
Other accrued and long-term liabilities	332	305
Deferred revenue	(24)	(44)
Net cash used in operating activities	(289)	(401)
Cash flows from investing activities:
Acquisition of property and equipment	(9)
Net cash used in investing activities	(9)
Cash flows from financing activities:
Proceeds from issuance of short-term debt		320
Payment on short-term debt		(40)
Net cash provided by financing activities		280
Net decrease in cash and cash equivalents	(298)	(121)
Cash and cash equivalents at beginning of period	335	285
Cash and cash equivalents at end of period	37	164
Supplementary disclosure of cash flow information:
Interest paid	1	2
Income tax paid	1	2
Non-cash financing and investing transactions:
Value of warrants issued on other long-term liabilities	212
Original issue discount on secured convertible promissory notes		$ 64

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Nature of Business and Summary of Significant Accounting Policies	1. Nature of business and summary of significant accounting policies Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign's solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign's platform can be deployed both on premise and as a cloud-based ("SaaS") service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company's products include SignatureOne® Ceremony® Server, the iSign® suite of products and services, including iSign® Enterprise, iSign® Console™, and Sign-it® programs. Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2018. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at September 30, 2019, the Company's accumulated deficit was $134,402. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of September 30, 2019, the Company's cash balance was $37. These factors raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Changes and Recent Accounting Pronouncements Accounting Standards Update No. 2019-01, Leases (Topic 842), Codification Improvements. The amendments in this Update include the following items: (1) determining the fair value of the underlying asset by lessors that are not manufacturers or dealers; (2) presentation on the statement of cash flows—sales-type and direct financing leases; and (3) transition disclosures related to Topic 250, Accounting Changes and Error Corrections. The amendments in ASU 2019-01 for Issue 1 affect all lessors that are not manufacturers or dealers (generally financial institutions and captive finance companies); for Issue 2, all lessors that are depository and lending entities within the scope of Topic 942; for Issue 3, all entities that are lessees or lessors. The effective date of the amendments in ASU 2019-01 are for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2019-01 effective January 1, 2019. The adoption of ASU 2019-01 had no impact on the Company's financial statements. Other Accounting Standards Updates issued in 2019 are not currently applicable to the Company, therefore implementation would not be expected to have a material impact on the Company's financial position, results of operations and cash flows.

Concentrations

Concentrations	9 Months Ended
	Sep. 30, 2019
Risks and Uncertainties [Abstract]
Concentrations	2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue Total Revenue 2019 2018 2019 2018 2019 2018 Customer #1 58 % 68 % 17 % 11 % 18 % 11 % Customer #2 24 % 17 % - - - - Customer #3 16 % - 16 % 12 % 11 % 12 % Customer #4 - - 29 % 28 % 29 % 24 % Customer #5 - 9 % 17 % 18 % 16 % 16 % Customer #6 - - - - - 10 % Total concentration 98 % 94 % 79 % 69 % 74 % 73 %

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Net Loss per Share	3. Net loss per share The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted net income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding. The following table lists shares and warrants that were excluded from the calculation of diluted earnings per share as the exercise of such options and warrants would be antidilutive: For the Three and Nine Months Ended September 30, September 30, Stock options 1,077 1,056 Warrants 2,812 1,828

Debt

Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Debt	4. Debt Advances: In April, May, and June 2018, the Company received, from investors, advances aggregating $115 in cash against certain accounts receivable of the Company. Upon collection of an invoice, the Company would repay the advance to the lenders on a pro rata basis together with a 5% advance fee. The receivables were collected and $40 of the advances were repaid in May 2018, along with $2 in advance fees per the agreement. The advance fees were recorded as interest expense in the quarter ended June 30, 2018. The remaining $75 advances were converted into secured convertible notes in August 2018. Notes payable: In August 2018, the Company issued secured convertible promissory notes to investors and affiliates of the Company aggregating $341, of which $205 was paid in cash, $75 was exchanged for the remaining advances described above and $61 was in the form of an Original Issue Discount ("OID") on these amounts. The secured notes are mandatorily convertible into Common Stock at a conversion rate of the lesser of $0.50 per share or the price per share of Common Stock upon closing a new financing of at least $1,000 in aggregate proceeds. The secured notes bear interest at the rate of 10% per annum, are due December 31, 2019 and are secured by an interest in all the Company's rights, title and interest in, to and under its intellectual property. Should the secured notes remain outstanding following the maturity date an additional 30% of the note's principal amount shall become due and payable. In December 2018, the Company issued short-term unsecured convertible promissory notes to investors and affiliates of the Company aggregating $346 in cash. The short-term notes are mandatorily convertible into Common Stock at a conversion rate of the lesser of $0.50 per share or the price per share of Common Stock, upon closing a new debt and/or equity financing of at least $1,000 in aggregate proceeds. The notes bear interest at the rate of 10% per annum and are due December 31, 2019. The Company used the funds received from the above financing for working capital and general corporate purposes. In June 2019, one noteholder sold its unsecured note in the amount of $400 plus accrued interest of $72 to six current investors, one of which is a related party. The original note was replaced by the issuance of new notes that continue to bear interest at the rate of 10% per annum and remain due December 31, 2019. During the three and nine months ended September 30, 2019, the Company accrued $65 and $188 of interest expense, of which $19 and $46 was to related parties and $46 and $142 was to other investors. During the three and nine months ended September 30, 2018, the Company accrued $45 and $125 of interest expense, of which $9 and $25 was to related parties and $36 and $100 was to other investors. The Company recorded $10 and $30 in debt discount amortization for the three and nine months ended September 30, 2019. The Company recorded $48 and $100 in debt discount amortization for the three and nine months ended September 30, 2018.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Equity (Deficit)	5. Stockholders' Equity (Deficit) Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended September 30, 2019 and 2018, was approximately 13.4% and 5.91%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized using the accrual method over the vesting period of the options. The Company granted 40 stock options during the nine months ended September 30, 2019 at a weighted average exercise price of $0.50 per share. The Company granted 393 stock options during the nine months ended September 30, 2018 at a weighted average exercise price of $0.78 per share. There were no stock options exercised during the three and nine months ended September 30, 2019 and 2018. The fair value calculations for the stock options granted are based on the following assumptions: Nine Months Ended Nine Months Ended Risk free interest rate 2.30 % 1.91 % Expected life (years) 6.13 6.30 Expected volatility 191.65 % 180.51 % Expected dividends None None The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three and nine-month periods ended September 30, 2019 and 2018. Three Months Ended Nine Months Ended 2019 2018 2019 2018 Research and development $ 6 $ 18 $ 24 $ 72 General and administrative 25 43 98 56 Director options 6 8 22 15 Stock-based compensation expense $ 37 $ 69 $ 144 $ 143 A summary of option activity under the Company's plans as of September 30, 2019 and 2018 is as follows: 2019 2018 Options Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 1,037 $ 1.65 $ - 736 $ 3.65 $ - Granted 40 $ 0.50 $ - 393 $ 0.78 $ - Forfeited or expired - $ - $ - (73 ) $ 14.86 $ - Outstanding at September 30 1,077 $ 1.61 5.22 $ - 1,056 $ 1.81 6.07 $ - Vested and expected to vest at September 30 1,072 $ 1.61 5.22 $ - 1,039 $ 1.78 6.06 $ - Exercisable at September 30 575 $ 2.45 4.95 $ - 256 $ 5.46 5.03 $ - The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2019: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Per Share Number Outstanding Weighted Average Exercise Price Per Share $0.01 – $25.00 1,049 5.31 $ 0.63 547 $ 0.61 $25.01 - $625.00 28 1.50 $ 38.81 28 $ 38.81 Total 1,077 5.22 $ 1.61 575 $ 2.45 The following table summarizes the Company's non-vested option shares as of September 30, 2019: Non-vested Option Shares Shares Weighted Average Non-vested at January 1, 2019 718 $ 0.64 Granted 40 $ 0.50 Vested (255 ) $ 0.63 Non-vested at September 30, 2019 503 $ 0.65 As of September 30, 2019, there was $112 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 1.44 years. Warrants On February 2, 2019, the Company issued warrants to purchase 985 shares of common stock to employees and consultants associated with their unpaid salaries and consulting fees. The warrants are only exercisable on a cashless basis if the warrant holder elects to exchange their deferred salaries and consulting fees. The Company ascribed a value of $212 to the warrants which is booked as a discount to other long-term liabilities in the balance sheet. The value of the warrants will be amortized to warrant expenses on long−term liabilities in the statement of operations over the life of the warrants. The warrants have a three year life and an exercise price of $0.50 per share. As of September 30, 2019, the Company has charged $47 of the warrant value to expense. A summary of the warrant activity for the nine months ended September 30 is as follows: September 30, 2019 September 30, 2018 Shares Weighted Average Exercise Price Per Share Shares Weighted Average Exercise Price Per Share Outstanding at beginning of period 1,828 $ 2.08 1,878 $ 2.46 Issued 985 $ 0.50 Expired - $ - (50 ) $ 15.63 Outstanding at end of period 2,813 $ 1.53 1,828 $ 1.59 Exercisable at end of period 2,813 $ 1.53 1,828 $ 1.59 A summary of the status of the warrants outstanding and exercisable as of September 30, 2019 is as follows: Number of Shares Issuable Under Warrants Weighted Average Remaining Life (years) Weighted Average Exercise Price per share 1,550 1.66 $ 2.18 278 0.01 $ 1.63 985 2.39 $ 0.50 2,813 1.75 $ 1.53 Forward Looking Statements Certain statements contained in this quarterly report on Form 10-Q, including, without limitation, statements containing the words "believes", "anticipates", "hopes", "intends", "expects", and other words of similar import, constitute "forward looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors which may cause actual events to differ materially from expectations. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2018, including the following: ● Technological, engineering, manufacturing, quality control or other circumstances that could delay the sale or shipment of products; ● Economic, business, market and competitive conditions in the software industry and technological innovations that could affect the Company's business; ● The Company's inability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the proprietary rights of the Company; and ● General economic and business conditions and the availability of sufficient financing. Except as otherwise required by applicable laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, as a result of new information, future events or otherwise.

Nature of Business and Summar_2

Nature of Business and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Nature of Business	Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign's solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign's platform can be deployed both on premise and as a cloud-based ("SaaS") service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company's products include SignatureOne® Ceremony® Server, the iSign® suite of products and services, including iSign® Enterprise, iSign® Console™, and Sign-it® programs.
Basis of Presentation	Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2018. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year.
Going Concern	Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at September 30, 2019, the Company's accumulated deficit was $134,402. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of September 30, 2019, the Company's cash balance was $37. These factors raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Accounting Changes and Recent Accounting Pronouncements	Accounting Changes and Recent Accounting Pronouncements Accounting Standards Update No. 2019-01, Leases (Topic 842), Codification Improvements. The amendments in this Update include the following items: (1) determining the fair value of the underlying asset by lessors that are not manufacturers or dealers; (2) presentation on the statement of cash flows—sales-type and direct financing leases; and (3) transition disclosures related to Topic 250, Accounting Changes and Error Corrections. The amendments in ASU 2019-01 for Issue 1 affect all lessors that are not manufacturers or dealers (generally financial institutions and captive finance companies); for Issue 2, all lessors that are depository and lending entities within the scope of Topic 942; for Issue 3, all entities that are lessees or lessors. The effective date of the amendments in ASU 2019-01 are for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2019-01 effective January 1, 2019. The adoption of ASU 2019-01 had no impact on the Company's financial statements. Other Accounting Standards Updates issued in 2019 are not currently applicable to the Company, therefore implementation would not be expected to have a material impact on the Company's financial position, results of operations and cash flows.

Concentrations (Tables)

Concentrations (Tables)	9 Months Ended
	Sep. 30, 2019
Risks and Uncertainties [Abstract]
Summary of accounts receivable and revenue concentrations	Accounts Receivable Total Revenue Total Revenue 2019 2018 2019 2018 2019 2018 Customer #1 58 % 68 % 17 % 11 % 18 % 11 % Customer #2 24 % 17 % - - - - Customer #3 16 % - 16 % 12 % 11 % 12 % Customer #4 - - 29 % 28 % 29 % 24 % Customer #5 - 9 % 17 % 18 % 16 % 16 % Customer #6 - - - - - 10 % Total concentration 98 % 94 % 79 % 69 % 74 % 73 %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Schedule of antidilutive excluded from calculation of earnings per share	For the Three and Nine Months Ended September 30, September 30, Stock options 1,077 1,056 Warrants 2,812 1,828

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of fair value calculations for the stock options granted	Nine Months Ended Nine Months Ended Risk free interest rate 2.30 % 1.91 % Expected life (years) 6.13 6.30 Expected volatility 191.65 % 180.51 % Expected dividends None None
Schedule of allocation of stock-based compensation expense	Three Months Ended Nine Months Ended 2019 2018 2019 2018 Research and development $ 6 $ 18 $ 24 $ 72 General and administrative 25 43 98 56 Director options 6 8 22 15 Stock-based compensation expense $ 37 $ 69 $ 144 $ 143
Schedule of option activity under the Company's plans	2019 2018 Options Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding at January 1, 1,037 $ 1.65 $ - 736 $ 3.65 $ - Granted 40 $ 0.50 $ - 393 $ 0.78 $ - Forfeited or expired - $ - $ - (73 ) $ 14.86 $ - Outstanding at September 30 1,077 $ 1.61 5.22 $ - 1,056 $ 1.81 6.07 $ - Vested and expected to vest at September 30 1,072 $ 1.61 5.22 $ - 1,039 $ 1.78 6.06 $ - Exercisable at September 30 575 $ 2.45 4.95 $ - 256 $ 5.46 5.03 $ -
Schedule of significant ranges of outstanding and exercisable options	Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Per Share Number Outstanding Weighted Average Exercise Price Per Share $0.01 – $25.00 1,049 5.31 $ 0.63 547 $ 0.61 $25.01 - $625.00 28 1.50 $ 38.81 28 $ 38.81 Total 1,077 5.22 $ 1.61 575 $ 2.45
Schedule of the company's non-vested shares	Non-vested Option Shares Shares Weighted Average Non-vested at January 1, 2019 718 $ 0.64 Granted 40 $ 0.50 Vested (255 ) $ 0.63 Non-vested at September 30, 2019 503 $ 0.65
Schedule of warrant activity	September 30, 2019 September 30, 2018 Shares Weighted Average Exercise Price Per Share Shares Weighted Average Exercise Price Per Share Outstanding at beginning of period 1,828 $ 2.08 1,878 $ 2.46 Issued 985 $ 0.50 Expired - $ - (50 ) $ 15.63 Outstanding at end of period 2,813 $ 1.53 1,828 $ 1.59 Exercisable at end of period 2,813 $ 1.53 1,828 $ 1.59
Schedule of warrants outstanding and exercisable	Number of Shares Issuable Under Warrants Weighted Average Remaining Life (years) Weighted Average Exercise Price per share 1,550 1.66 $ 2.18 278 0.01 $ 1.63 985 2.39 $ 0.50 2,813 1.75 $ 1.53

Nature of Business and Summar_3

Nature of Business and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Nature of Business and Summary of Significant Accounting Policies (Textual)
Accumulated deficit	$ (13,440)	$ (133,589)
Cash balance	$ 37	$ 335	$ 164	$ 285

Concentrations (Details)

Concentrations (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Accounts Receivable [Member]
Concentration Risk [Line Items]
Total concentration			98.00%	94.00%
Accounts Receivable [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration			58.00%	68.00%
Accounts Receivable [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration			24.00%	17.00%
Accounts Receivable [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration			16.00%
Accounts Receivable [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration				9.00%
Accounts Receivable [Member] | Customer #6 [Member]
Concentration Risk [Line Items]
Total concentration
Total Revenue [Member]
Concentration Risk [Line Items]
Total concentration	79.00%	69.00%	74.00%	73.00%
Total Revenue [Member] | Customer #1 [Member]
Concentration Risk [Line Items]
Total concentration	17.00%	11.00%	18.00%	11.00%
Total Revenue [Member] | Customer #2 [Member]
Concentration Risk [Line Items]
Total concentration
Total Revenue [Member] | Customer #3 [Member]
Concentration Risk [Line Items]
Total concentration	16.00%	12.00%	11.00%	12.00%
Total Revenue [Member] | Customer #4 [Member]
Concentration Risk [Line Items]
Total concentration	29.00%	28.00%	29.00%	24.00%
Total Revenue [Member] | Customer #5 [Member]
Concentration Risk [Line Items]
Total concentration	17.00%	18.00%	16.00%	16.00%
Total Revenue [Member] | Customer #6 [Member]
Concentration Risk [Line Items]
Total concentration				10.00%

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock options [Member]
Anti-diluted earnings per share of stock options and warrants shares	1,077	1,056	1,077	1,056
Warrants [Member]
Anti-diluted earnings per share of stock options and warrants shares	2,812	1,828	2,812	1,828

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					3 Months Ended		9 Months Ended
	Dec. 31, 2018	Aug. 31, 2018	Jun. 30, 2018	May 31, 2018	Apr. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Aggregating amount of debt			$ 115	$ 115	$ 115
Debt instrument, description								Upon collection of an invoice, the Company would repay the advance to the lenders on a pro rata basis together with a 5% advance fee. The receivables were collected and $40 of the advances were repaid in May 2018, along with $2 in advance fees per the agreement. The advance fees were recorded as interest expense in the quarter ended June 30, 2018. The remaining $75 advances were converted into secured convertible notes in August 2018.
Secured notes due date								Dec. 31, 2019
Accrued interest expense						$ 65	$ 45	$ 188	$ 125
Accrued interest to related parties						19	9	46	25
Accrued Interest to other investors						46	36	142	100
Amortization of debt discount						$ 10	$ 48	$ 30	$ 100
Unsecured notes										$ 400
Accrued interest										$ 72
Interest rate										10.00%
Secured Convertible Promissory Notes [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Aggregating amount of debt	$ 346	$ 205
Debt instrument, description		The maturity date an additional 30% of the note's principal amount shall become due and payable.
Issued secured convertible promissory notes		$ 341
Conversion rate per shares	$ 0.50	$ 0.50
Aggregate proceeds of new financing	$ 1,000	$ 1,000
Secured notes bear interest rate	10.00%	10.00%
Secured notes due date	Dec. 31, 2019	Dec. 31, 2019
Original issue discounts		$ 61
Amount exchanged for advances		$ 75

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) (Details)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Stockholders Equity Deficit
Risk free interest rate	2.30%	1.91%
Expected life (years)	6 years 1 month 16 days	6 years 3 months 19 days
Expected volatility	191.65%	180.51%
Expected dividends

Stockholders' Equity (Deficit_2

Stockholders' Equity (Deficit) (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 37	$ 69	$ 144	$ 143
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	6	18	24	72
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	25	43	98	56
Director options [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 6	$ 8	$ 22	$ 15

Stockholders' Equity (Deficit_3

Stockholders' Equity (Deficit) (Details 2) - Option [Member] - USD ($) shares in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Shares
Outstanding, Beginning balance	1,037	736
Granted	40	393
Forfeited or expired		(73)
Outstanding, Ending Balance	1,077	1,056
Vested and expected to vest, Ending balance	1,072	1,039
Exercisable, Ending balance	575	256
Weighted Average Exercise Price Per share
Outstanding, Beginning balance	$ 1.65	$ 3.65
Granted	0.50	0.78
Forfeited or expired		14.86
Outstanding, Ending balance	1.61	1.81
Vested and expected to vest, Ending balance	1.61	1.78
Exercisable, Ending balance	$ 2.45	$ 5.46
Weighted Average Remaining Contractual Term (Years)
Outstanding, Ending balance	5 years 2 months 19 days	6 years 26 days
Vested and expected to vest, Ending balance	5 years 2 months 19 days	6 years 22 days
Exercisable, Ending balance	4 years 11 months 12 days	5 years 11 days
Aggregate Intrinsic Value
Outstanding, Beginning balance
Granted
Forfeited or expired
Outstanding, Ending balance
Vested and expected to vest, Ending balance
Exercisable, Ending balance

Stockholders' Equity (Deficit_4

Stockholders' Equity (Deficit) (Details 3) shares in Thousands	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	1,077
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	5 years 2 months 19 days
Options Outstanding, Weighted Average Exercise Price	$ 1.61
Options Exercisable, Number Outstanding | shares	575
Options Exercisable, Weighted Average Exercise Price	$ 2.45
$0.01 - $25.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	0.01
Range of Exercise Prices, Upper Range Limit	$ 25
Options Outstanding, Number Outstanding | shares	1,049
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	5 years 3 months 22 days
Options Outstanding, Weighted Average Exercise Price	$ 0.63
Options Exercisable, Number Outstanding | shares	547
Options Exercisable, Weighted Average Exercise Price	$ 0.61
$25.01 - $625.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Range Limit	25.01
Range of Exercise Prices, Upper Range Limit	$ 625
Options Outstanding, Number Outstanding | shares	28
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	1 year 6 months
Options Outstanding, Weighted Average Exercise Price	$ 38.81
Options Exercisable, Number Outstanding | shares	28
Options Exercisable, Weighted Average Exercise Price	$ 38.81

Stockholders' Equity (Deficit_5

Stockholders' Equity (Deficit) (Details 4) shares in Thousands	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Shares
Non-vested, Beginning balance | shares	718
Granted | shares	40
Vested | shares	(255)
Non-vested, Ending balance | shares	503
Weighted Average Grant-Date Fair Value
Non-vested, Beginning balance | $ / shares	$ 0.64
Granted | $ / shares	0.50
Vested | $ / shares	0.63
Non-vested, Ending balance | $ / shares	$ 0.65

Stockholders' Equity (Deficit_6

Stockholders' Equity (Deficit) (Details 5) - Warrant [Member] - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Outstanding at beginning of period	1,828	1,878
Shares, Issued	985
Shares, Expired		(50)
Shares, Outstanding at end of period	2,813	1,828
Shares, Exercisable at end of period	2,812	1,828
Weighted Average Exercise Price Per Share, Outstanding at beginning of period	$ 2.08	$ 2.46
Weighted Average Exercise Price Per Share, Issued	0.50
Weighted Average Exercise Price Per Share, Expired		15.63
Weighted Average Exercise Price Per Share, Outstanding at end of period	1.53	1.59
Weighted Average Exercise Price Per Share, Exercisable at end of period	$ 1.53	$ 1.59

Stockholders' Equity (Deficit_7

Stockholders' Equity (Deficit) (Details 6) shares in Thousands	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Shares Issuable Under Warrants | shares	2,813
Weighted Average Remaining Life (years)	1 year 9 months
Weighted Average Exercise Price per share | $ / shares	$ 1.53
Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Number of Shares Issuable Under Warrants | shares	1,550
Weighted Average Remaining Life (years)	1 year 7 months 28 days
Weighted Average Exercise Price per share | $ / shares	$ 2.18
Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Number of Shares Issuable Under Warrants | shares	278
Weighted Average Remaining Life (years)	4 days
Weighted Average Exercise Price per share | $ / shares	$ 1.63
Warrants Group Three [Member]
Class of Warrant or Right [Line Items]
Number of Shares Issuable Under Warrants | shares	985
Weighted Average Remaining Life (years)	2 years 4 months 20 days
Weighted Average Exercise Price per share | $ / shares	$ 0.50

Stockholders' Equity (Deficit_8

Stockholders' Equity (Deficit) (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Feb. 02, 2019
Stockholders' Equity (Deficit) (Textual)
Total unrecognized compensation cost	$ 112
Weighted average period	1 year 5 months 9 days
Estimated average forfeiture rate	13.40%	5.91%
Ascribed a value of warrants	$ 47		$ 212
Exercise price			$ 0.50
Warrants term	3 years
Warrants to purchase			985
Stock options [Member]
Stockholders' Equity (Deficit) (Textual)
Granted, shares	40	393
Granted, weighted average exercise price per share	$ 0.50	$ 0.78